Elite PharmaceuticalsELTP -5.20%60 PEG Ratio is 1.07 as of Jul. 03, 2026, which is 4% below its 10-year median of 1.12. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.56 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 349 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 65.62% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Elite Pharmaceuticals's PEG Ratio or its related term are showing as below:
ELTP'
s PEG Ratio Range Over the Past 10 Years
Min: 1.07 Med: 1.12 Max: 1.24
Current: 1.07
During the past 13 years, Elite Pharmaceuticals's highest PEG Ratio was 1.24. The lowest was 1.07. And the median was 1.12.
ELTP's PEG Ratio is ranked better than 65.62% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs ELTP: 1.07
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Elite Pharmaceuticals (OTCPK:ELTP) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Elite Pharmaceuticals (ELTP) has a PEG Ratio of 1.07 as of Jul. 03, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Elite Pharmaceuticals and its competitors. This is near median its historical median of 1.12. Over the past decade, Elite Pharmaceuticals' PEG Ratio has ranged from 1.07 to 1.24. According to the industry distribution chart, Elite Pharmaceuticals ranks #120 out of 349 companies in the Drug Manufacturers industry, placing it in the top 34.4%.
Is Elite Pharmaceuticals' PEG Ratio too high?
Elite Pharmaceuticals' current PEG Ratio of 1.07 is near median its 10-year median of 1.12. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 1.24. The Drug Manufacturers industry median PEG Ratio is 1.71. Elite Pharmaceuticals' value of 1.07 is 37.4% below this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #120 out of 349 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' PEG Ratio compare to EBS and NIKA?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #120 out of 349 companies for PEG Ratio. This puts Elite Pharmaceuticals in the upper half of its industry. The industry median PEG Ratio is 1.71. Elite Pharmaceuticals' value of 1.07 is 37.4% below this benchmark. Historically, Elite Pharmaceuticals' own PEG Ratio has ranged from 1.07 to 1.24 over the past decade. While the company's 10-year median is 1.12 vs. the industry median of 1.71, Elite Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current PEG Ratio of 1.07 is 37.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current PEG Ratio is 1.07, which is near median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.56, compared to a current price of $0.34 — trading 39.1% below its estimated fair value. The current PEG Ratio is 1.07, which is near median its 10-year median of 1.12 and 37.4% below the Drug Manufacturers industry median of 1.71. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current PEG Ratio is 1.07 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.34 is trading 39.1% below its estimated GF Value™ of $0.56.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
PEG Ratio: 1.07 (near median its 10-year median of 1.12)
GF Value™: $0.56 vs. price of $0.34 (39.1% below fair value)
Industry Position: 37.4% below the Drug Manufacturers median (#120 of 349)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
